Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

In a retrospective observational study, researchers compared autologous hematopoietic cell transplantation versus CAR-T therapy in patients with relapsed diffuse large B-cell lymphoma in complete remission. Autologous hematopoietic cell transplantation was associated with higher 2-year progression-free survival rates, a lower incidence of relapse, and higher 2-year overall survival rates. The researchers concluded that these data support the consideration of autologous hematopoietic cell transplantation in this patient population.